NCT02684981 is a clinical trial in Atrial Fibrillation, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT02684981?

NCT02684981 is sponsored by Boehringer Ingelheim.

What condition does NCT02684981 study?

NCT02684981 studies Atrial Fibrillation, Stroke.

Is NCT02684981 still recruiting?

NCT02684981 is currently completed. Last updated 24 July 2019.

Are results published for NCT02684981?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-07-24 · How we verify

NCT02684981

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient Convenience Study (RE-SONANCE)

Completed Results posted Last updated 24 July 2019

What this trial tests

trial in Atrial Fibrillation in 9,472 participants. Completed in 1 June 2017.

Timeline

11 November 2015

Primary endpoint
1 June 2017

1 June 2017

Quick facts

Lead sponsor	Boehringer Ingelheim
Status	Completed
Study type	OBSERVATIONAL
Enrollment	9,472
Start date	11 November 2015
Primary completion	1 June 2017
Estimated completion	1 June 2017
Sites	12 locations across Czechia, Poland, Israel, Russia, Hungary, Austria, Estonia, Slovenia

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Stroke — all drugs for Stroke →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 milligrams or 150 milligrams twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, et al · · 2020 · cited 6× · PMID 32257246 · DOI 10.1136/openhrt-2019-001202
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, et al · · 2021 · PMID 33929686 · DOI 10.1007/s11239-021-02450-2

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02684981 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 24 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02684981.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing